The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Stoke Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $6.23 Mil. Stoke Therapeutics's average Accounts Receivable for the
three
months ended in Mar. 2026 was $5.19 Mil.
Hence, Stoke Therapeutics's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.20.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Stoke Therapeutics Receivables Turnover Related Terms
Stoke Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Stoke Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STOK vs VRDN, ZLAB, NUVB: Receivables Turnover Comparison
For the Biotechnology subindustry, Stoke Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stoke Therapeutics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Stoke Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stoke Therapeutics (STOK) has a Receivables Turnover of 1.20 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Stoke Therapeutics and its competitors. According to the industry distribution chart, Stoke Therapeutics ranks #449 out of 839 companies in the Biotechnology industry, placing it in the top 53.5%.
Is Stoke Therapeutics' Receivables Turnover too high?
Stoke Therapeutics' current Receivables Turnover is 1.20. The Biotechnology industry median Receivables Turnover is 5.27. Stoke Therapeutics' value of 1.20 is 77.2% below this industry median. Based on the distribution chart, Stoke Therapeutics ranks #449 out of 839 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Stoke Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stoke Therapeutics' Receivables Turnover compare to VRDN and ZLAB?
According to the Biotechnology industry distribution chart, Stoke Therapeutics ranks #449 out of 839 companies for Receivables Turnover. This places Stoke Therapeutics in the lower half of its industry. The industry median Receivables Turnover is 5.27. Stoke Therapeutics' value of 1.20 is 77.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stoke Therapeutics's current Receivables Turnover of 1.20 is 77.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Stoke Therapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stoke Therapeutics's current Receivables Turnover is 1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stoke Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Stoke Therapeutics (STOK) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.14, compared to a current price of $33.02 — trading 225.6% above its estimated fair value. The current Receivables Turnover is 1.20 and 77.2% below the Biotechnology industry median of 5.27. Stoke Therapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Stoke Therapeutics (STOK), the current Receivables Turnover is 1.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stoke Therapeutics (STOK) Overvalued in 2026?
Based on GuruFocus' analysis, Stoke Therapeutics stock appears to be overvalued.
The current stock price of $33.02 is trading 225.6% above its estimated GF Value™ of $10.14.
GuruFocus considers Stoke Therapeutics to be Significantly Overvalued.
Key valuation signals for STOK:
Receivables Turnover: 1.20
GF Value™: $10.14 vs. price of $33.02 (225.6% above fair value)
Industry Position: 77.2% below the Biotechnology median (#449 of 839)
No single metric tells the full story. See the STOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
45GF Score
Get the complete analysis for STOK
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STOK has been successfully added to your 
